APP and Alzheimer disease: Although it is now clear that proteolytic processing of APP is complex [6,7,8,9] and no clinical trial of anti-Aβ drugs have shown any clear benefits to date [10], Aβ remains a prime AD therapeutic target [11,12] and continues to garner research efforts and interests.